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Introduction: Obstructive sleep apnoea (OSA) is common in obesity and is associated with
cardiovascular and metabolic complications. Continuous positive airway pressure (CPAP)
in OSA may lead to physiological changes reﬂected in the urinary proteome. The aim of
this study was to characterise the urinary proteome in severely obese adult subjects with
OSA who were receiving CPAP compared with severely obese subjects without OSA.
Methods: Severely obese subjects with and without OSA were recruited. Subjects with OSA were
receiving CPAP. Body composition and blood pressure measurements were recorded. Urinary
samples were analysed by Capillary Electrophoresis–Mass Spectrometry (CE–MS).
Results: Twenty-seven subjects with OSA-on-CPAP (age 4977years, BMI 4377 kg/m2) and 25
controls without OSA (age 5279years, BMI 3974 kg/m2) were studied. Age and BMI were not
signiﬁcantly different between groups. Mean CPAP use for OSA patients was 14.571.0 months.
Metabolic syndrome was present in 14(52%) of those with OSA compared with 6(24%) of controls
(p¼0.039). A urinary proteome comprising 15 peptides was identiﬁed showing differential
expression between the groups (po0.01). Although correction for multiple testing did not reach
signiﬁcance, sequences were determined for 8 peptides demonstrating origins from collagens,
ﬁbrinogen beta chain and T-cadherin that may be associated with underlying cardiovascular
disease mechanisms in OSA.
Conclusions: The urinary proteome is compared in OSA with CPAP and without OSA in severe
obesity. The effects of CPAP on OSA may lead to changes in the urinary peptides but further
research work is needed to investigate the potential role for urinary proteomics in characteris-
ing urinary peptide proﬁles in OSA.
& 2015 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license
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In obstructive sleep apnoea (OSA), episodes of recurrent upper
airway obstruction cause intermittent hypoxia, with frequent
sleep arousals and fragmented sleep, resulting in excessive
daytime hypersomnolence [1]. OSA has been increasing in
prevalence, and it has been estimated that 13% of men and
6% of women between the ages of 30 and 70 years have
moderate to severe forms of OSA [2]. This has been linked
with the growing obesity prevalence as it is known that obesity
is a risk factor for OSA. The prevalence of OSA in severe obesity
has been estimated to be between 40% and 90% [3,4]. OSA is
associated with hypertension, cardiovascular disease, type 2
diabetes and metabolic impairment [5].
It is known that OSA is independently associated with
arterial hypertension and this may be related to repeated
hypoxia and reoxygenation episodes that may cause ischae-
mia–reperfusion injury, as well as increased sympathetic
activity, inﬂammation and oxidative stress [6]. The kidney
has a role in blood pressure regulation and may be sensitive
to the effects of intermittent hypoxia [7]. Nocturnal hypoxia
may be associated with loss of kidney function [8], and a
positive relationship has been observed between impaired
glomerular ﬁltration and desaturation frequency, suggesting
an association between OSA and chronic kidney impairment
[9]. Histological changes in renal glomeruli have been reported
in severely obese patients with OSA [7], that may be related to
pressor responses and endothelial dysfunction in OSA [10].
Capillary electrophoresis coupled to mass spectrometry
(CE–MS) is a sensitive proteomic analytical technique that is
robust with high reproducibility of results in an acceptable
time frame [11]. In CE–MS, capillary zone electrophoresis is
interfaced with high resolution mass spectrometry; electro-
phoretic separation of peptides is performed by CE according
to charge and size, and the peptides are separated by
application of high voltage and analysed in the mass spectro-
meter [11]. The accuracy, precision, selectivity, sensitivity,
reproducibility, and stability of the CE–MS measurements
have been previously demonstrated [12]. CE–MS has been
widely used to study biomarker panels of urinary peptides for
conditions such as coronary artery disease [13] and chronic
kidney disease [14] that may indicate the presence of the
relevant condition [15].
We have previously used CE–MS to characterise the
urinary proteome in severe obesity with and without OSA,
and to determine if there were signiﬁcant differences in
urinary peptide proﬁles that may potentially relate to OSA.
24 peptides were found to be differentially distributed
between the two groups although these differences did not
reach signiﬁcance after correction for multiple testing.
Sequences were determined for 8 peptides demonstrating
origins from collagens and ﬁbrinogen alpha [16]. The pro-
teome in OSA prior to treatment may have been inﬂuenced
by the effects of OSA potentially inﬂuencing the peptide
panel and it was important to ascertain if there were changes
in the urinary peptide panel with continuous positive airway
pressure (CPAP) treatment.
CPAP therapy can improve glomerular hyperﬁltration in OSA
patients [17], perhaps by reducing renal renin-angiotensionsystem (RAS) activity, suggesting a potential effect of CPAP on
kidney function [18]. The sensitivity of the kidney to repetitive
intermittent hypoxia may inﬂuence the urinary proteome in
OSA, and it is conceivable that the effects of CPAP treatment in
OSA may lead to physiological changes reﬂected by the urinary
proteome. Deﬁning this in patients on CPAP may be useful as it
would potentially reﬂect effects of CPAP on various mechan-
isms, such as RAS activity, oxidative stress, and endothelial
dysfunction [19].
The use of urinary CE–MS analyses to study the urinary
proteome in adult OSA and severe obesity with CPAP therapy
has not been previously investigated. In this paper, we sought
to investigate the hypothesis that the urinary peptide pat-
terns were different between the two groups. To achieve this
goal, we characterised the urinary proteome in severely obese
subjects with OSA who were receiving CPAP compared to
subjects without OSA.2. Methods
2.1. Research design
This was a case-control study comparing patients who were
on effective CPAP treatment with subjects without OSA. The
research involved patient recruitment and sampling, and
subsequent CE–MS urinary proteome analyses.
2.2. Ethics statement
The study was approved by the research ethics committee
(NRES 13/NW/0589) and was performed in accordance with
the Declaration of Helsinki 2008. All patients gave written
informed consent.
2.3. Participants
Severely obese patients from the weight management and
sleep clinics at University Hospital Aintree were recruited from
March 2012 to January 2013. Patients were selected according to
the inclusion and exclusion criteria as assessed according to
the clinical history, physical examination and analysis of the
medical notes. At baseline, all subjects had spirometry testing
and overnight polysomnography to conﬁrm or refute the
diagnosis of OSA. All subjects with OSA at baseline were
previously untreated for their OSA and they were offered CPAP.
All OSA subjects on CPAP and non-OSA subjects were followed-
up from September 2013 to February 2014.
Patients were eligible if they were Z21 years old and had
body mass index (BMI)Z35 kg/m2. Patients who were over-
weight or had mild obesity were not included because the
majority of the patients were recruited from the hospital
weight management service which manages patients with
severe obesity. Exclusion criteria were patients with cardio-
respiratory disease; current smokers or those with more than
10 pack years smoking history; kidney and liver disease;
acute illnesses and pregnancy. Based on the exclusion cri-
teria, we sought to control for potential confounders that may
affect the interpretation of the urinary proteome including
coronary artery disease, coexisting respiratory illness, renal
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who were not CPAP treatment or not compliant with their
CPAP treatment were excluded from the analysis. Likewise,
patients who had bariatric surgery were excluded from
subsequent analysis as our aim was to study urinary pro-
teome in subjects who were receiving CPAP treatment
(CPAPZ4 h per night) and non-OSA subjects.2.4. Sample size
Although no previous studies evaluating the effect of CPAP on
the adult urinary proteome using CE–MS in OSA and obesity
have been performed, previous urinary proteomic work in
paediatric OSA have investigated sample sizes of n¼11–30
per group [20,21]. Therefore, we aimed for a minimum of 25
subjects per group.2.5. Protocol
All patients attended a study visit day between 0800 and 1000 h
and underwent a detailed history and physical examination.
Body composition measurements, anthropometry, fasting blood
and urine sampling and venous blood gases (to assess for
hypercarbia) were performed. Daytime somnolence was
assessed using an Epworth Sleepiness Scale Questionnaire
(ESS) where a score 410 indicated increased sleepiness. To
ensure comparability and uniformity of assessments of patients,
body composition, anthropometry and sampling were carried
out at the same time at each study visit.2.5.1. Blood pressure
Blood pressure was measured at the arm in a sitting position
after a rest for at least 5 min at 1 min intervals between each
measurement, using an oscillometric digital blood pressure
monitor (HEM-705CP, Omron, Japan). The mean of three
measurements was calculated.2.5.2. Body measurements
All measurements were performed in triplicate. Weight and
height were measured without shoes and with light clothing.
Other measurements included neck circumference at the level
of the laryngeal prominence; waist circumference midway
between the lower rib and iliac crest; and hip circumference
was measured horizontally over the widest part of the gluteal
region. The tape measure was ensured to be snug and not
compressing the skin, parallel to the ﬂoor with measurement
at the end of a normal expiration. Body composition measure-
ments used bioimpedance scales (TBF-521, TANITA, Tokyo,
Japan). This method has been previously validated [22].2.5.3. Biochemical measurements
Serum samples were collected using standard phlebotomy
vials and immediately sent to the pathology laboratory for
analysis in accordance with local protocol and standards.
Serum biochemistry was measured using standard laboratory
assays (Roche, UK). Blood gases were analysed with a Cobas
Blood Gas Analyser (Roche, UK).2.5.4. Metabolic syndrome
Subjects were assessed for metabolic syndrome according to
the National Cholesterol Education Program (NCEP) guide-
lines [23]. Patients had metabolic syndrome if three or more
risk factors were present: waist circumference (males4102
cm; females488 cm), triglyceridesZ1.7 mmol/l, high density
lipoprotein (HDL) cholesterol (maleso1.04 mmol/l; fema-
leso1.3 mmol/l), blood pressure Z130/Z85 mmHg, and fast-
ing glucose Z6.1 mmol/l.2.5.5. Baseline sleep studies and spirometry
All subjects previously had overnight multichannel respira-
tory limited polysomnography (PSG) (Somnoscreen Digital
PSG acquisition system, Version 2.0, SomnoMedics, Rander-
sacker, Germany) and spirometry (Spiro Air LT system,
Medisoft, Sorinnes, Belgium) to conﬁrm or refute OSA.
Apnoea was deﬁned as a cessation of airﬂow for 410 s.
Hypopnoea was deﬁned as a 50% reduction in airﬂow accom-
panied by a 44% desaturation and a reduction in chest wall
movement. OSA was diagnosed if the apnoea-hypopnoea
index (AHI) was Z5.2.5.6. CPAP therapy
Patients with OSA received standard CPAP therapy with S8/S9
Escape machines (ResMed, Abingdon, UK). CPAP compliance
was based upon usage in hours per night (h/night) at the
prescribed pressure. Compliance data was recorded by the
CPAP machines and was downloaded using ResScan software
(Version 4.2, ResMed, Abingdon, UK). This was assessed at
each patient's most recent routine CPAP compliance/adher-
ence clinic. Adequate compliance was deﬁned as a usage
time of44 h/night on470% of nights in the treatment group.2.6. CE–MS materials and methods
2.6.1. Urine sample preparation
Spontaneously voided urine samples for CE–MS analyses
were collected at the study visit using urine Monovettes
(Sarstedt, Nümbrecht, Germany). Second void samples were
collected at the same time each morning (09:00 h) after an
overnight fast for 8 h, at their study visit prior to the admin-
istration of any medication. The samples were stored at
80 1C in urine Monovettes until the sample preparation
stage. Sample preparation for proteomic analysis was per-
formed as previously described [24]. In this process, each
0.7 mL aliquot of urine was thawed immediately before use
and diluted with 0.7 mL of 2 M urea, 10 mM NH4OH contain-
ing 0.02% SDS. Each sample was ultraﬁltered (2000 g, 60 min,
4 1C) to remove higher molecular mass proteins, such as
albumin and immunoglobulin G using Centrisart ultracentri-
fugation ﬁlter devices (20 kDa MW) (Sartorius stedim Biotech,
Goettingen, Germany) until 1.1 mL of ﬁltrate was obtained.
The ﬁltrate from each sample was then applied onto separate
PD-10 desalting columns (GE Healthcare, Uppsala, Sweden)
equilibrated in 0.01% NH4OH in HPLC-grade H2O to decrease
matrix effects by removing urea, electrolytes, and salts, and
to enrich polypeptides present. Finally, all samples were
lyophilised, and stored at 4 1C.
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Samples were re-suspended in HPLC-grade H2O shortly before
CE–MS analyses, as described [24]. CE–MS analysis was
performed using a P/ACE MDQ capillary electrophoresis
system (Beckman Coulter, Fullerton, USA) using a 90 cm
360 μm OD, 50 μm ID non-coated silica capillary with a
tapered tip (New Objective, Woburn, USA) coupled to a
microTOF MS (Bruker Daltonic, Bremen, Germany) [24]. A
solution of 20% acetonitrile (Sigma-Aldrich, Taufkirchen,
Germany) in HPLC-grade water with 0.94% formic acid
(Sigma-Aldrich) was used as running buffer. The ESI sprayer
(Agilent Technologies, Palo Alto, CA, USA) was grounded, and
the ion spray interface potential was set between 4 and
4.5 kV. Data acquisition and MS acquisition methods were
automatically controlled by the CE via contact-close-relays.
For each sample, spectra were accumulated every 3 s, over a
range of m/z 350–3000 over 60 min [24]. The accuracy, preci-
sion, selectivity, sensitivity, reproducibility, and stability of
the CE–MS measurements have been previously demon-
strated [12].
2.6.3. CE–MS data processing
Mass spectra were processed using MosaiquesVisu software
(Mosaiques Diagnostics, Germany), including peak picking,
deconvolution and deisotoping [25]. The software automati-
cally examined all mass spectra from a CE–MS analysis for
signals above the threshold (Signal-Noise-Ratio44). Only
signals that were present in 3 consecutive spectra were
accepted. The isotopic distribution was assessed and charge
was assigned based on the isotopic distribution, using a
matched ﬁltering algorithm. This operation resulted in a list
of signals deﬁned by mass/charge, charge, migration time,
and signal intensity (relative abundance deﬁned by ion
counts). This list was transformed into a dataset containing
only mass, migration time, and signal intensity; signals that
represent the same compound but with a different charge
state were combined.
To allow for compilation and comparison of samples,
normalised signal intensity was used as a measure of relative
abundance. CE migration time and ion signal intensities of
the samples were calibrated and normalised using internal
polypeptide standards by linear regression [26]. ‘Housekeep-
ing’ peptides that consistently appear in urine samples and
are unaffected by disease states provided ideal reference
mapping points for CE migration times [15]. Data sets were
accepted only if they passed a strict quality control criteria: a
minimum of 950 chromatographic features (mean number of
features minus one standard deviation) must be detected
with a minimal MS resolution of 8000 (required resolution to
resolve ion signals with zr6) in a minimal migration time
interval (the time window, in which separated signals can be
detected) of 10 min. After calibration, the mean deviation of
migration time (compared to reference standards) was below
0.35 min [24]. The resultant peak list included molecular mass
(Da), normalised CE migration time (min) and normalised
signal intensity for each peptide. All results were annotated
into a Microsoft SQL database for statistical analysis.
Peptide proﬁles for OSA and non-OSA patients were
compared for signiﬁcant differences. Subsequently, the iden-
tity of the peptides was determined by matching against anvalidated database that was previously developed using
liquid chromatography–MS/MS analysis on a quadrupole
time-of-ﬂight mass spectrometer [15]. These human urinary
peptide sequences can be accessed at (http://mosaiques-
diagnostics.de/diapatpcms/mosaiquescms/front_content.
php?idcat¼257).2.7. Statistical analysis
Patient demographics were summarised by OSA group as
means (SD) (or median (IQR) if non-normal) for continuous
variables and frequencies (%) for categorical variables. Com-
parisons between groups were performed using a t-test for
continuous variables which were normally distributed and a
Mann–Whitney test for those that were not. Categorical
variables were tested using a Chi-Square or Fishers Exact test
depending on the expected frequencies. Assessment for
normal distribution of patient data was by Shapiro–Wilks
testing. Statistical signiﬁcance for patient data was assigned
at po0.05. Statistical analyses were carried out using SPSS
version 20 (IBM Corp, Armonk, NY, USA).
For proteomics analyses, the non-parametric Wilcoxon
test has been shown to be well-suited for proteomics data
sets [27], and was used to determine signiﬁcance in peptide
abundance between the groups. Statistical signiﬁcance was
assigned at pr0.01. Given the large number of possible
peptides present, assessment of differences included an
adjustment for multiple testing. Correction for multiple test-
ing to account for false positives (false discovery rate) was
performed using the Benjamini–Hochberg test.3. Results
Fifty-three subjects who had been assessed at baseline were
recruited. One urinary sample could not be analysed by CE–
MS and therefore was excluded from the analysis. Therefore,
52 patients were entered into the study; 27 with OSA who
were on CPAP and 25 without OSA (non-OSA) (Fig. 1). All
subjects were of white European ethnicity. Patients attended
their follow-up after a median of 15 (IQR 13,16) months. For
patients with OSA, the mean CPAP use was 14.5 months (SD
1.0) and mean CPAP use per night was 4.6 h (SD 0.6). Mean
CPAP pressure was 10 cmH20 (SD 1.0).
Clinical and biochemical parameters of the 52 patients
according to those without OSA (non-OSA) and OSA-on-CPAP
groups are presented in Table 1. The groups did not signiﬁ-
cantly differ in age, BMI and gender. More OSA subjects on
CPAP had metabolic syndrome, particularly meeting the
waist circumference, blood pressure, HDL and triglycerides
components of the criteria. Although OSA subjects tended to
have higher waist circumference, neck circumference, waist:
hip ratio and body fat percentage by bioimpedance, these
differences were not statistically signiﬁcant. Smoking, dia-
betes, alcohol consumption and medication use were similar
between groups.
Non- OSA (n=25) 
6 declined to participate 
OSA on CPAP >4hrs 
per night (n=27) 
19 declined to participate
1 patient died
Found to be ineligible:
1 commenced smoking, 
3 post-bariatric surgery
5 did not tolerate CPAP 
4 CPAP usage <4hrs/night 
Patients with severe 
obesity and OSA 
approached (n=61) 
Patients with severe 
obesity and without 
OSA (non- OSA) 
approached (n=31)
1 urine sample not processed
Fig. 1 – Study proﬁle.
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3.1.1. Peptide identiﬁcation
We detected 1041 different peptides that were consistently
found in more than 70% of the samples in at least one of the
groups. The compiled urinary proteomic data from OSA on
CPAP and non-OSA patients is shown in (Fig. 2). We found 15
peptides with signiﬁcant unadjusted Wilcoxon p-values (all
pr0.01) (Fig. 3). Although our initial data analysis showed a
signiﬁcant differential distribution in these peptides, it did
not pass the more strict adjustment for multiple testing.
Sequences were determined for 8 peptides demonstrating
origins mainly from collagen alpha chains. The 15 peptides
are presented as in Table 2. The table contains the mass, the
CE migration time, the peptide sequence, the name of the
protein fragment, the SwissProt entry, the accession number,
mean amplitude (ion signal intensity) and differential fre-
quency of peptides within each group. Frequency was calcu-
lated based on the number of times each peptide was
observed in each group. Mean amplitude was calculated
based on the total signal intensity observed for each peptide
divided by the number of subjects in each group.4. Discussion
We used CE–MS to compare urinary proﬁles in severely obese
adult subjects with OSA who were on effective CPAP and
subjects without OSA at follow-up after a median of 15
months. To our knowledge, this is the ﬁrst study to char-
acterise the adult human urinary proteome in patients
treated with CPAP and also to compare this in subjects
without OSA. We were able to identify a urinary peptide
pattern of 15 peptides that were candidates for differential
distribution between the two groups with signiﬁcant unad-
justed Wilcoxon p-values, though these differences did not
reach signiﬁcance after correction for multiple testing. Never-
theless, the trends in the peptide panel characterise differ-
ences in the two groups studied. We identiﬁed sequences for
8 of these peptides that comprised breakdown products of
collagen, as well as ﬁbrinogen and a cadherin subtype. Theseﬁndings may represent the urinary proteome in OSA subjects
on CPAP compared with subjects without OSA. The observed
urinary peptide panel relating to CPAP-treated OSA and non-
OSA groups suggests that there may be a potential role for
CE–MS in the proteomic study of urinary proﬁles in OSA.
The ﬁndings from this study extend what is known about
the urinary proteome in OSA and severe obesity. Using CE–
MS, we previously observed a panel of peptides in a study of
severely obese subjects with and without OSA [16]. In the
present study, the characterised urinary proteome with CPAP
comprised a similar make-up of collagens and a peptide
related to ﬁbrinogen. Additionally, one peptide for which no
sequence data is as yet available was found to be present in
the peptide panel in both studies. The nature of peptides that
constitute both panels may relate to the underlying vascular
changes present in OSA including sympathetic activation,
oxidative stress and inﬂammation [6].
In this study, the majority of the identiﬁed peptides were
fragments of collagen alpha-1 (I) and (III) in addition to
ﬁbrinogen beta chain and cadherin 13 (T-Cadherin) peptides.
Fibrinogen beta chain has a role in ﬁbrinogen synthesis and
haemostasis, blood viscosity as a binding surface for proteins
and as an extracellular matrix component, and may be
associated with cardiovascular risk factors [28]. T-Cadherin
is highly expressed in the vasculature including endothelial
cells, has been implicated in the modulation of angiogenic
activities and is associated with circulating levels of adipo-
nectin that is important for vascular homoeostasis. Addition-
ally, links between T-cadherin and blood pressure, lipids,
metabolic syndrome, type 2 diabetes and ischaemic stroke
have been found in genome-wide association studies [29]. It
should be noted that the mean amplitude of ﬁbrinogen beta
chain and cadherin-13 was lower in the CPAP-treated
patients and it is possible that this may reﬂect decreased
breakdown or differential expression with treatment.
The extracellular matrix contains a ﬁbrillar collagen net-
work that is regulated by ﬁbroblasts and myoﬁbroblasts.
Changes in vasoactive peptides and proinﬂammatory cyto-
kines, and activity of enzymes that process procollagen
precursors to mature collagen including procollagen protei-
nases and collagen degradation enzymes (matrix
Table 1 – Patient demographics were summarised by treated OSA and non-OSA groups as means (SD) (or median (IQR) if
non-normal) for continuous variables and frequencies (%) for categorical variables. Signiﬁcant p-values are highlighted
in bold.
Patient characteristics
Non-OSA
(n¼25)
OSA on CPAP
(n¼27)
p-Value
Age (years) 52 (9) 49 (7) 0.2252
Gender: male 13 (52%) 15 (56%) 0.7972
Smoked in past 6 (24%) 7 (26%) 0.8727
Alcohol intake: o8 units per week 17(68%) 19 (70%) 0.8532
BMI (kg/m2) 39(4) 43(7) 0.186
Neck circumference (cm) 42.1(4.3) 44.2 (4.6) 0.0916
Waist:hip ratio 0.94 (0.1) 0.98 (0.1) 0.2009
Body fat (%) TANITA scales 42.8 (8.8) 44.4 (8.4) 0.5029
Diabetes 5 (20%) 9 (33%) 0.2788
Hypertension 5 (20%) 6 (22%) 0.8446
BP-lowering medications 5 (20%) 6 (22%) 0.8446
Glucose-lowering therapy 5 (20%) 9 (33%) 0.2788
Lipid-lowering medications 8 (32%) 9 (33%) 0.9184
Metabolic syndrome 6 (24%) 14(52%) 0.0391
Cardio-respiratory parameters
Systolic BP (mmHg) 128 (11) 129 (11) 0.9684
Diastolic BP (mmHg) 82 (8) 79 (7) 0.2276
Mean Arterial Pressure (mmHg) 100 (91,104) 98 (93,101) 0.161
Heart rate (beats per min): 71 (10) 74 (10) 0.2775
CPAP use per night (h) – 4.6 (0.6) –
CPAP pressures (cmH2O) – 10 (1.0) –
Epworth sleep score: 4 (3, 9) 3 (2, 11) 0.5015
O2 saturations (%): 97 (96,99) 97 (96,98) 0.918
PCO2 (kPa) 5.4 (5.1, 5.6) 5.3 (5.1, 5.5) 0.3882
AHI at baseline 2.4 (1.6, 3.7) 24.6 (14.0, 43.6) o0.001
Metabolic parameters
Albumin Creatinine Ratio (mg/mmol) 0.4 (0.2, 0.5) 0.5 (0.3, 0.8) 0.1475
Creatinine (micromol/l) 77 (13) 78 (15) 0.8252
MDRD-GFR (mL/min/1.73 m2) 87 (13) 89 (15) 0.542
Low density lipoprotein (mmol/l) 2.7 (1.1) 2.6 (0.9) 0.7637
High density lipoprotein (mmol/l) 1.3 (0.4) 1.2 (0.3) 0.3228
HbA1c (mmol/mol) 37 (34, 40) 38 (35, 48) 0.1466
Total cholesterol (mmol/l) 4.7 (1.1) 4.6 (1.0) 0.7119
Fasting glucose (mmol/l) 5.4 (5.1, 5.9) 5.4 (4.7, 6.0) 0.8905
Thyroid stimulating hormone (mU/l) 2.2 (1.3) 2.1 (0.9) 0.9275
Triglycerides (mmol/l) 1.2 (0.8, 2.0) 1.6 (1.0,2.6) 0.1634
Bicarbonate (mmol/l) 24.0 (1.8) 24.2 (2.1) 0.6896
Highly sensitive C-Reactive Protein (hsCRP) (mg/L) 3.3 (1.1, 6.8) 3.0 (1.6, 5.8) 0.8189
Abbreviations: AHI: Apnoea-Hypopnoea index, BMI: body mass index, BP: blood pressure, CPAP: continuous positive airway pressure, HbA1c:
glycated haemoglobin, MDRD-GFR: Glomerular Filtration Rate using Modiﬁcation of Diet in Renal Disease Equation, PCO2: partial pressure of
carbon dioxide.
S l e e p S c i e n c e 8 ( 2 0 1 5 ) 5 8 – 6 7 63metalloproteinases) may account for the excretion of urinary
collagen fragments [30]. Furthermore, it is known that altera-
tions of the myocardial collagen matrix may occur in cardi-
ovascular disease that may result in perturbations in vascular
function [30]. In this context, it is known that OSA is
associated with cardiovascular disease [31], and the peptides
in the peptide panel may be a reﬂection of underlying
cardiovascular changes associated with CPAP.
The mechanisms underlying the observed urinary peptide
proﬁle in this study remain unclear, but may be related to the
treatment effects of CPAP on intermittent hypoxia and sys-
temic hypertension. Post-translational modiﬁcation of proteins
has been postulated as amechanism by which protein function
is inﬂuenced by chronic intermittent hypoxia, and there isevidence that this induces changes in the phosphorylation
state of proteins associated with transcriptional activation,
signal transduction pathways, and neurotransmitter synthesis
[32]. Multiple lines of evidence underscore the importance of
CPAP treatment in lowering BP in patients with severe OSA [33].
Additionally, OSA-mediated hypertension may be inﬂuenced
by the effects of CPAP on reducing renin-angiotensin system
activity with changes in renal perfusion [17,18]. It is conceivable
that the treatment effects of CPAP on OSA disease progression
may lead to the modiﬁcation of proteins and changes in
protease activity, and renal effects that may be reﬂected in
the urinary proteome [15].
This study was limited by the lack of serial measurements
of urine samples throughout the follow-up period and by
Fig. 2 – Compiled 3-dimensional depiction of urinary peptide proﬁle for non-OSA (A) and OSA-on-CPAP (B). The X axis
represents CE migration time (min), Y-axis represents molecular mass (KDa, on a logarithmic scale), and the Z-axis represents
mean signal intensity. (A) Non-OSA. (B) OSA-on-CPAP.
Fig. 3 – 3-dimensional proﬁle of 15 peptides that showed signiﬁcant differences between non-OSA (A) and OSA-on-CPAP (B)
groups. The X axis represents CE migration time (minutes), Y-axis represents molecular mass (KDa, on a logarithmic scale),
and the Z-axis represents mean signal intensity. In order to demonstrate differences between the 15 peptides, Figs. 2 and 3
are not of similar scale. (A) Non-OSA. (B) OSA-on-CPAP.
S l e e p S c i e n c e 8 ( 2 0 1 5 ) 5 8 – 6 764the presence of potential confounders such as metabolic
syndrome and patient medications. It may be argued that
the excretion of urinary peptides may vary during the day,
because of physical activity, diet, or medications taken. We
sought to control for this by sampling all participants at the
same time each morning, at second void, after an overnight
fast at their study visit prior to the administration of any
medication. We envisaged that it was important for the
urinary polypeptide panel to reﬂect ‘real-life’ clinical patients
for it to be relevant and applicable. Therefore, controlling forevery potential confounding factor would not have been
pragmatic and would have limited recruitment of potential
participants. Repeat polysomnography was not conducted to
prove if the AHI was sufﬁciently reduced on CPAP but the
patients were managed according to local hospital protocol
and were already established on their treatment at follow-up,
with improved symptoms and ESS scores as assessed at their
compliance/adherance clinic visits.
There were more patients in the CPAP-treated OSA group
who had metabolic syndrome than non-OSA patients. This
Table 2 – The table lists the peptide identiﬁcation number (Peptide ID), experimental mass (in Da) and CE migration time (in min) for the 15 peptides in the OSA panel. For all
sequence-identiﬁed peptides, the amino acid sequence, the name of the protein precursor and the amino acid positions within the protein's primary sequence (according
to SwissProt) are presented. Frequency was based on the occurrence of each peptide within each group. Mean amplitude calculated based on the mean signal intensity of
the peptide within each group.
Peptide
ID
Peptide
mass
(Da)
CE time
(min)
Unadjusted
Wilcoxon p-
value
Area
under
the
curve
Benjamini
and
Hochberg
p- value
Sequence Protein
name
Start
amino
acid
Stop
amino
acid
SwissProt name Accession
number
Frequency
OSA on
CPAP
Mean
amplitude
OSA on
CPAP (SD)
Frequency
non-OSA
Mean
amplitude
non-OSA
(SD)
61039 1813.715 31.69499 0.000532 0.77 0.499525 1.0 1557 (656) 1.0 2616 (1196)
55756 1700.721 29.93699 0.00096 0.76 0.499525 GmpGSp
GGpGSDGKpGPpG
Collagen
alpha-1
(III) chain
537 555 CO3A1_HUMAN gi124056490 1.0 913 (265) 1.0 1200 (292)
130747 3359.578 31.89787 0.001473 0.75 0.511072 PpGADGQ
PGAKGEpGDAG
AKGDAGPp
GPAGPAGPpGPIG
Collagen
alpha-1(I)
chain
816 854 CO1A1_HUMAN gi124056487 0.8 699 (487) 0.9 1237 (625)
167576 4759.125 29.94851 0.002237 0.73 0.582167 0.7 69 (58) 0.3 24 (38)
15593 1066.478 25.95367 0.003683 0.72 0.645249 GDRGEpGPpGP Collagen
alpha-1(I)
chain
800 810 CO1A1_HUMAN gi124056487 0.77 82 (88) 0.4 68 (205)
11249 980.2951 35.57253 0.004019 0.73 0.645249 0.8 529 (405) 1.0 808 (295)
54269 1675.708 29.20317 0.004713 0.72 0.645249 GpPGPpGTS
GHpGSpGSpG
Collagen
alpha-1
(III) chain
180 198 CO3A1_HUMAN gi124056490 1.0 259 (87) 1.0 200 (112)
131294 3375.574 31.91691 0.005008 0.72 0.645249 0.9 942 (569) 1.0 1311 (538)
90651 2385.054 33.94877 0.006009 0.72 0.645249 1.0 779 (399) 0.9 1168 (571)
88299 2339.085 22.66349 0.006386 0.72 0.645249 KGNSGEPGApGSK
GDTGAKGEpGPVG
Collagen
alpha-1(I)
chain
430 455 CO1A1_HUMAN gi124056487 0.8 102 (62) 0.6 63 (88)
87411 2321.165 22.05962 0.007984 0.70 0.645249 DKKREEAP
SLRPAPPPISGGGY
FGB
protein
(Fragment)
0.4 42 (69) 0.7 113 (125)
32874 1333.416 36.10802 0.008054 0.71 0.645249 0.7 186 (155) 0.8 321 (184)
19969 1132.569 24.0363 0.008187 0.70 0.645249 PGKEGPpGPQGP Collagen
alpha-1
(XXII)
chain
1221 1232 COMA1_HUMAN gi296434458 0.7 49 (48) 0.4 20 (29)
91249 2401.078 24.0189 0.008734 0.70 0.645249 0.7 46 (50) 0.3 16 (26)
57584 1738.76 25.0428 0.009298 0.71 0.645249 FVHARTPHA
EDmAEL
Cadherin-
13
0.8 711 (477) 1.0 1115 (396)
SD: standard deviation. FGB: ﬁbrinogen beta chain. OSA-on-CPAP: subjects with obstructive sleep apnoea receiving CPAP. Non-OSA: subjects without obstructive sleep apnoea.
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S l e e p S c i e n c e 8 ( 2 0 1 5 ) 5 8 – 6 766was attributable to a combination of factors including waist
circumference, blood pressure and lipid proﬁles. It would be
difﬁcult to separate metabolic syndrome from OSA in severe
obesity as these conditions are closely associated. The incor-
poration of such factors in the discovery process may poten-
tially lead to peptide proﬁles that may be more representative
of patients with OSA in the severely obese population.
This study was limited by the relatively small sample size.
Additionally, we did not directly compare the urine proteome
in OSA patients directly before commencing CPAP treatment
with ﬁndings after CPAP. However, it must be emphasised
that this was foremost a discovery study, with the aim to use
CE–MS to investigate urinary proﬁles in severely obese sub-
jects with OSA who were receiving CPAP in relation to
subjects without OSA. Our ﬁndings provide a novel insight
into urinary peptide patterns in a well-characterised cohort of
severely obese patients with OSA who received CPAP, and
subjects without OSA. As this study was based on samples
collected from patients at a speciﬁc point in time, a cause-
and-effect relationship between the observed urinary pro-
teome and CPAP itself cannot be established. Nevertheless, it
would have been ethically questionable to perform a rando-
mised placebo-CPAP controlled study comparable to our
duration of CPAP use (41 year) which is a strength of
this study.5. Conclusion
The ﬁndings from this study provide a unique insight of the
urinary proteome in OSA with CPAP. The identiﬁed peptide
panel includes collagen, cadherin and ﬁbrinogen subtypes
that may be related to mechanisms underlying cardiovascu-
lar disease in OSA. This may be associated with the treatment
effects of CPAP on OSA disease progression inﬂuencing the
expression of urinary peptides. There is a potential role for
urinary proteomics in characterising urinary peptide proﬁles
in OSA. Further work is still needed to investigate the use of
proteomic methods in deﬁning peptide proﬁles that reﬂect
OSA and in the presence of CPAP that may potentially
support CPAP treatment monitoring and progress or relating
to the changes in cardiovascular risk proﬁles, potentially
translating into better monitoring of OSA treatment and aid
in the care of patients with sleep disorders.Funding
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